PE20071230A1 - Combinaciones y metodos de inhibidores del vhc - Google Patents

Combinaciones y metodos de inhibidores del vhc

Info

Publication number
PE20071230A1
PE20071230A1 PE2007000143A PE2007000143A PE20071230A1 PE 20071230 A1 PE20071230 A1 PE 20071230A1 PE 2007000143 A PE2007000143 A PE 2007000143A PE 2007000143 A PE2007000143 A PE 2007000143A PE 20071230 A1 PE20071230 A1 PE 20071230A1
Authority
PE
Peru
Prior art keywords
dimethyl
amino
rotamer
tautomer
interferon
Prior art date
Application number
PE2007000143A
Other languages
English (en)
Inventor
Emilio Anthony Emini
Michael James Flint
Anita Yee Mei Howe
Bruce A Malcolm
Stanley L Mullen
Robert Orville Ralston
Xiao Tong
Original Assignee
Schering Corp
Viropharma Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Viropharma Inc, Wyeth Corp filed Critical Schering Corp
Publication of PE20071230A1 publication Critical patent/PE20071230A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL ARN DEL VIRUS DE LA HEPATITIS C (VHC) TAL COMO 5-CICLOPROPIL-2-(4-FLUORO-FENIL)-6-[(2-HIDROXIETIL)-METANSULFONILAMINO]-BENZOFURAN-3-CARBOXILICO O UN ROTAMERO, TAUTOMERO U OTRA FORMA ISOMERICA O UNA SAL DE LOS MISMOS Y UN INHIBIDOR DE LA PROTEASA DEL VHC TAL COMO (1R,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[2(S)-[[[(1,1-DIMETIETIL)AMINO]CARBONIL]AMINO]3,3-DIMETIL-1-OXOBUTIL]6.6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2(S)-CARBOXAMIDA O UN ENANTIOMERO, ESTEREOISOMERO, ROTAMERO, TAUTOMERO, COMPUESTO RACEMICO U OTRA FORMA ISOMERICA O UNA SAL DE LOS MISMOS. LA COMPOSICION PUEDE CONTENER ADEMAS OTRO AGENTE BIOLOGICAMENTE ACTIVO TAL COMO INTERFERON, PEG-INTERFERON O RIBAVIRINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA HEPATITIS C Y TRASTORNOS AFINES
PE2007000143A 2006-02-09 2007-02-09 Combinaciones y metodos de inhibidores del vhc PE20071230A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77192706P 2006-02-09 2006-02-09
US84178906P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
PE20071230A1 true PE20071230A1 (es) 2008-01-16

Family

ID=38261665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000143A PE20071230A1 (es) 2006-02-09 2007-02-09 Combinaciones y metodos de inhibidores del vhc

Country Status (7)

Country Link
US (1) US20070224167A1 (es)
EP (1) EP1981523A2 (es)
AR (1) AR059430A1 (es)
CL (1) CL2007000361A1 (es)
PE (1) PE20071230A1 (es)
TW (1) TW200808308A (es)
WO (1) WO2007092645A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659461A1 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
NZ586232A (en) * 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
MX2010006736A (es) 2007-12-21 2010-10-15 Avila Therapeutics Inc Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CN101910145A (zh) * 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010031832A2 (en) * 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
AR073603A1 (es) * 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
US8841302B2 (en) 2009-04-06 2014-09-23 Ptc Therapeutics, Inc. HCV inhibitor and therapeutic agent combinations
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
BR112018017228A2 (pt) 2016-03-04 2019-02-05 Univ Leland Stanford Junior composições e métodos para regeneração do músculo usando prostaglandina e2
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7675491A (en) * 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
WO2004041201A2 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
AU2004285019B9 (en) * 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
WO2005067454A2 (en) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection

Also Published As

Publication number Publication date
US20070224167A1 (en) 2007-09-27
TW200808308A (en) 2008-02-16
WO2007092645A3 (en) 2007-10-04
AR059430A1 (es) 2008-04-09
WO2007092645A2 (en) 2007-08-16
CL2007000361A1 (es) 2008-01-25
EP1981523A2 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
PE20071230A1 (es) Combinaciones y metodos de inhibidores del vhc
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
HRP20191939T1 (hr) Postupci za liječenje hepatitisa c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
AR049635A1 (es) (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
PE20140038A1 (es) Compuestos antivirales
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
CL2012001449A1 (es) Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion.
JP2009506071A5 (es)
RU2009141187A (ru) Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
HK1176318A1 (en) Injection device
EA200501105A1 (ru) Фармацевтическая композиция
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
MX2009005798A (es) Recuperacion de apoplejia.
JP2018502856A5 (es)
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina

Legal Events

Date Code Title Description
FD Application declared void or lapsed